Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001213900-25-036075
Filing Date
2025-04-28
Accepted
2025-04-28 16:10:13
Documents
16
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K ea0239394-10ka1_cero.htm   iXBRL 10-K/A 363019
2 CERTIFICATION ea023939401ex31-3_cero.htm EX-31.3 3183
3 CERTIFICATION ea023939401ex31-4_cero.htm EX-31.4 3187
  Complete submission text file 0001213900-25-036075.txt   666885

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cero-20241231.xsd EX-101.SCH 3836
5 XBRL DEFINITION FILE cero-20241231_def.xml EX-101.DEF 17738
6 XBRL LABEL FILE cero-20241231_lab.xml EX-101.LAB 37822
7 XBRL PRESENTATION FILE cero-20241231_pre.xml EX-101.PRE 19543
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0239394-10ka1_cero_htm.xml XML 9051
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-40877 | Film No.: 25880413
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)